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Abstract
 
Cow’s milk allergy in children is often of short duration, which makes this disorder an interesting
clinical model for studies of tolerance to dietary antigens. Here, we studied T cell responses in
21 initially allergic children who, after a milk-free period of 
 
 
 
2 mo, had cow’s milk reintro-
duced to their diet. Children who outgrew their allergy (tolerant children) had higher frequencies
of circulating CD4
 
 
 
CD25
 
 
 
 T cells and decreased in vitro proliferative responses to bovine
 
 
 
-lactoglobulin in peripheral blood mononuclear cells (PBMCs) compared with children who
maintained clinically active allergy. No significant difference in proliferative activity stimulated
by the polyclonal mitogen phytohemagglutinin was observed between the two groups. Depletion
of CD25
 
 
 
 cells from PBMCs of tolerant children led to a fivefold increase in in vitro proliferation
against 
 
 
 
-lactoglobulin. This suggests that tolerance is associated with the appearance of cir-
culating CD4
 
 
 
CD25
 
 
 
 regulatory T (Treg) cells that are capable of suppressing the effector T
cells generated 1 wk after reintroduction of cow’s milk. The suppressive function of the
CD4
 
 
 
CD25
 
 
 
 Treg cells was shown to be partly cell contact dependent. Collectively, our study
provides human data to suggest that mucosal induction of tolerance against dietary antigens is
associated with the development of CD4
 
 
 
CD25
 
 
 
 Treg cells.
Key words: human • oral tolerance • regulatory T cells • food allergy • cytokines
 
Introduction
 
The usual immune response to harmless gut antigens is
generation of local and systemic immunological tolerance
known as “oral tolerance.” This mechanism may be ex-
plained by different T cell events such as anergy, clonal
deletion, and induction of regulatory T (Treg) cells. For
ethical reasons, the existence of oral tolerance in humans is
mainly supported by circumstantial evidence. Thus, healthy
individuals have hardly any hyperactivated T cells in their
gut mucosa, very little mucosal IgG production, and only
low levels of serum IgG antibodies to food antigens (1).
Moreover, nasal antigen application or feeding experiments
induced peripheral down-regulation of T cell responses in
healthy individuals (2, 3).
Decreased robustness of mucosally induced tolerance in
“westernized” populations is suggested by the recent strik-
ing rise of atopic diseases (4), and some 5–8% of children
up to 3 yr of age now develop food allergy. This disorder
is associated with serious health consequences and may
unfortunately also be the starting point for an “allergic
march,” i.e., the development of subsequent atopic diseases
in the airways. Therefore, it is of great importance to un-
derstand the immunological mechanisms involved in break
of oral tolerance against dietary antigens.
Indirect evidence exists to suggest that the development
of food allergy may be controlled by CD4
 
 
 
CD25
 
 
 
 Treg
cells. Patients with immune dysregulation, polyendocrin-
opathy, enteropathy, X-linked syndrome, or X-linked au-
toimmunity-allergic dysregulation syndrome lack this T
cell subset, and they often develop food allergic reactions
and increased specific IgE antibody levels accompanied
by severe eczema (5, 6). Further support for a role of
CD4
 
 
 
CD25
 
 
 
 Treg cells in mediating oral tolerance has
been obtained from feeding experiments in mice (7–11).
Other T cell subsets possibly involved in oral tolerance, at
least in animals, are Th3 cells which produce TGF-
 
 
 
, Tr1
cells which produce IL-10, and TGF-
 
 
 
 and NK T cells
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(12–14). However, it is not firmly established whether all
these subsets represent separate cell lineages or different
maturational phenotypes.
A few years after the discovery of naturally occurring
CD4
 
 
 
CD25
 
 
 
 Treg cells in mice, a similar T cell subset has
been identified in human peripheral blood, thymus, LNs, and
cord blood (15). In mice, the CD4
 
 
 
CD25
 
 
 
 Treg cells re-
portedly play a role in the control of immune responses to in-
fectious agents, transplants, and cancer as well as in graft-ver-
sus-host reactions (16–21), whereas in humans CD4
 
 
 
CD25
 
 
 
Treg cells have been shown to be involved in regulating can-
cer immunity (22–24). These human cells are typically aner-
gic upon TCR stimulation (25), although recent studies in
mice suggest that Treg cells can be expanded both in vitro
and in vivo when interacting with the appropriate APC
type  (26). This might explain why a constant number of
CD4
 
 
 
CD25
 
 
 
 Treg cells is maintained in the circulation.
Common phenotypic markers of CD4
 
 
 
CD25
 
 
 
 Treg
cells are CD45RO, L-selectin (CD62L), CTLA-4 (CD152),
CD25, and glucocorticoid-induced tumor necrosis factor
receptor (27–30), although the same phenotypic profile can
also be displayed by other T cell subsets. Therefore, only
functional assays can firmly identify CD4
 
 
 
CD25
 
 
 
 Treg
cells. Nevertheless, recent studies in mice and humans have
demonstrated that a novel transcription-repressor protein,
FOXP3, is exclusively expressed by naturally occurring and
induced CD4
 
 
 
CD25
 
 
 
 Treg cells (31–38).
Current evidence suggests that human CD4
 
 
 
CD25
 
 
 
 Treg
cells employ several mechanisms to suppress immune re-
sponses, for instance, via direct cell contact or indirectly by
reducing the antigen-presenting capacity of APCs (39). In ad-
dition, at least in mice, suppressive cytokines appear to be in-
volved in the effector function of Treg cells (40, 41). It
remains an open question whether one or more of these
down-regulatory properties may be acquired by any naive
CD4
 
 
 
 T cell in a normal peripheral immunostimulatory process.
Cow’s milk allergy in children is often a disease of rela-
tively short duration, which makes it an interesting clinical
model for the development of oral tolerance. Using deple-
tion of CD25
 
 
 
 cells as a read-out test for the suppressive ef-
fect that the Treg subset exerts on effector T cells, we were
able to show that children who had outgrown their allergy
(i.e., are now tolerant against cow’s milk allergens), devel-
oped a population of CD4
 
 
 
CD25
 
 
 
 T cells with regulatory
function in their peripheral blood 1 wk after an in vivo milk
challenge. This subset was numerically and functionally re-
duced in children who remained allergic to cow’s milk.
These results suggested mucosal induction of Treg cells in
response to cow’s milk proteins or, alternatively, that cen-
trally generated Treg cells had become activated and ex-
panded in children with outgrown food allergy.
 
Materials and Methods
 
Patient Characteristics and Selection Criteria
 
A total number of 21 children (median age 24 mo, range 6–56
mo) previously diagnosed as having cow’s milk allergy were in-
cluded consecutively in the study as they routinely visited the
out-patient clinic just before starting a trial of reintroduction of
cow’s milk and cow’s milk products into the diet after at least 2
mo (median 6 mo, range 2–11 mo) on a strictly cow’s milk-free
diet. All families were routinely informed by a nutrition physiol-
ogist and given an information brochure about how to achieve a
diet free from cow’s milk products.
The original allergy diagnosis had been made at a median age
of 5 mo (range 2–18 mo) based on the following criteria: persis-
tent gastroenterological symptoms without, or in combination
with, extraintestinal symptoms (see next paragraph) reported by
the parents, followed by total disappearance of these symptoms
on cow’s milk-free diet for a period of at least 1 mo, and then fol-
lowed by reappearance of similar symptoms by at least two open
milk challenges observed by the parents (see next paragraph).
Children with a history of anaphylactic symptoms or evidence of
cow’s milk-specific IgE antibodies were excluded to make the
test group as homogeneous as possible.
The patients had demonstrated one or more of the following
symptoms (number of cases in parenthesis): bloody and usually
loose stools (
 
n
 
 
 
  
 
4), diarrhea (
 
n
 
 
 
  
 
8), failure to thrive (
 
n
 
 
 
  
 
5),
eczema (
 
n
 
 
 
  
 
2), vomiting or regurgitation (
 
n
 
 
 
  
 
5), excessive cry-
ing (
 
n
 
 
 
  
 
5), and anemia (
 
n
 
 
 
  
 
1). The symptoms had been ob-
served by the parents from a median age of 3 mo (range 2 wk–12
mo). Where suspected, lactose intolerance was excluded by rou-
tine lactose challenge test (H2 breath test).
 
Cow’s Milk Challenge Procedure
 
The reintroduction of cow’s milk into the diet was done grad-
ually, increasing the amount of milk or cow’s milk-based formula
to at least 100 ml/day during the first two days, continuing until
the parents experienced unacceptable symptoms or until a routine
evaluation was performed at the out-patient clinic after 1 wk. All
these clinical evaluations were performed by the same pediatri-
cian, and 8 children (median age 24 mo, range 16–45 mo) were
deemed to display persistently active cow’s milk allergy, whereas
13 children (median age 24 mo, range 9–49 mo) had outgrown
their allergy since they were now found to be tolerant to the milk
challenge. A blood sample was taken just before and 1 wk after
the start of cow’s milk reintroduction.
 
Ethics
 
The study was approved by the local Regional medical ethics
committee (East Norway, Blindern, pb1139, Norway), and in-
formed consent was obtained from the parents.
 
Cell Isolation
 
PBMCs were obtained from heparinized blood by Lympho-
prep centrifugation (Nycomed Pharma). Cells were washed and
finally diluted in RPMI-1640 medium supplemented with 10%
heat-inactivated pooled human serum, 1% 
 
l
 
-glutamine, and 1%
gentamycin (GIBCO BRL).
 
Proliferation Assay
 
PBMCs (10
 
5
 
) were cultured in 96-well round-bottom tissue cul-
ture plates (200 
 
 
 
l/well) and stimulated with phytohemaggluti-
nin (PHA; 10 
 
 
 
l, 100 
 
 
 
g/ml) or 
 
 
 
-lactoglobulin (
 
 
 
-LG; 10 
 
 
 
l,
20 mg/ml) from cow’s milk (L0130; Sigma-Aldrich). Radioac-
tive thymidine (
 
3
 
H-Tdr, 1 mCi/well, TRK 120; Amersham Bio-
sciences) was added to the wells 6 d after the initiation of stimula-
tion. The cells were harvested 12–16 h later. Incorporation of
 
3
 
H-Tdr was determined in a 
 
 
 
-counter. 
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Depletion of CD25
 
 
 
 Cells
 
An Ab-coated microbead isolation procedure was used for deple-
tion of CD25
 
 
 
 cells, according to the manufacturer’s instruction
(Miltenyi Biotec). Briefly, 20 
 
 
 
l of CD25-specific beads were
suspended together with 5 
 
 
 
 10
 
6
 
–10
 
7
 
 PBMCs and incubated for
15 min on ice, followed by two washes. LD columns were pre-
pared as recommended by the manufacturer and used for mag-
netic depletion. The effluent PBMC samples contained 
 
 
 
0.5%
CD25
 
 
 
 cells as determined by flow cytometry (see below). Unre-
lated microbeads, i.e., specific for mouse CD5 (Miltenyi), were
used to prepare control samples of PBMCs.
 
Antibodies
 
The following mouse mAbs with specificity for human mole-
cules were used for immunostaining of PBMCs: FITC- and PE-
conjugated anti-CD25 (IgG1, clone 2A3; Becton Dickinson);
biotin-conjugated anti–CTLA-4 (IgG1, clone BNI3.1; Becton
Dickinson); PerCp anti-CD3 (IgG1) and biotin-conjugated anti-
CCR4 (IgG1, clone 1G1; Becton Dickinson); FITC- and APC-
conjugated anti-CD4 (IgG2a, clone EDU-2; Diatec); FITC- and
PE-conjugated anti-CD8 (IgG2a, clone UCH-T4; Diatec); PE-
conjugated anti-CD45RO (IgG2a, clone UCHL-1; LeukoSite
Inc.); anti-CCR9 (IgG2b, clone 3C3; LeukoSite); anti-
 
 
 
4
 
 
 
7
(IgG1, Act 1; courtesy of Dr. A.I. Lazarovits, University of West-
ern Ontario, London, Ontario, Canada); and PE/FITC-conju-
gated streptavidin (Southern Biotechnology). Secondary reagents
were goat anti–mouse IgG2b-PE (Southern Biotechnology) and
goat anti–mouse IgG1-PE (Catalog Laboratories).
 
Flow Cytometric Analysis and Cell Sorting
 
Immunofluorescence staining was performed after washing the
cells with PBS plus 0.5% (wt/vol) BSA (Sigma-Aldrich). Cells
were incubated for 20 min on ice with a pretitrated optimal dilu-
tion of each mAb. Cells were washed again and then analyzed by
flow cytometry (FACS Caliber; Becton Dickinson). Immuno-
stained subsets of T cells were sorted with FACS
 
®
 
 Vantage SE
(Becton Dickinson).
 
Transwell Experiments
 
Transwell experiments were performed in 24-well plates with
a 0.4-
 
 
 
m pore size (Costar Inc.). FACS
 
®
 
-sorted CD4
 
 
 
CD25
 
 
 
cells (4 
 
 
 
 10
 
5
 
) were added to the lower chamber. FACS-sorted
CD4
 
 
 
CD25
 
 
 
 cells (10
 
5
 
) with a purity 
 
 
 
99% were added either
directly to the lower chamber (together with the CD4
 
 
 
CD25
 
 
 
subset) or placed in the upper transwell chamber. After 48 h of
stimulation with anti-CD3/CD28 beads (10
 
6
 
 beads/well; Dynal-
biotech), the cells in the lower chambers were transferred to a
96-well plate and radioactive thymidine was added for 12–16 h.
Incorporation of 
 
3
 
H-Tdr was determined in a 
 
 
 
-counter.
 
Cytokine Analysis
 
PBMCs (5 
 
 
 
 10
 
5
 
) were cultured in flat 24-well plates (1 ml/
well) and stimulated with PHA (50 
 
 
 
g/ml) or 
 
 
 
-LG (1 mg/ml)
or remained unstimulated in medium alone for 96 h. The super-
natants were collected and frozen at 
 
 
 
70
 
 
 
C until analysis by the
following assays.
 
TGF-
 
 
 
.
 
An ELISA was performed in round-bottom wells
coated overnight with a pretitrated optimal concentration of mAb
to human TGF-
 
 
 
 in its inactive complex (anti–TGF-
 
 
 
1-LAP; 2
 
 g/ml, clone 27235.1; RD System Europe Ltd.). The supernatants
and standard recombinant TGF-  (RD System Europe) were seri-
ally diluted in PBS-Tween and incubated overnight at 4 C. A bio-
tinylated mouse mAb to human TGF- 1-LAP (125 ng/ml, clone
27240; RD System Europe) was added to the wells and incubated
overnight at 4 C. The wells were than incubated with a Streptavi-
din-horseradish peroxidase conjugate (RD System Europe) for 20
Figure 1. Frequency of circulating CD4 CD25  T cells before and 1 wk
after in vivo challenge with cow’s milk. (A) PBMCs were purified from
blood before and after the challenge, immunostained with mAbs, and
then analyzed with FACS® Caliber. The M1 gates were set in accordance
with isotype- and concentration-matched mAb controls. One representa-
tive experiment is shown for the tolerant group (n   10) and one for the
allergic group (n     7). (B) Increase or decrease of circulating
CD4 CD25  T cells 1 wk after in vivo exposure to cow’s milk normal-
ized in relation to the prechallenge levels (set to 100%, dotted line). Stu-
dent’s t test was used for statistical analysis.CD25  Treg Cells in Food Allergy 1682
min in room temperature. Finally, TMB (Microwell Peroxidase
Substrate System; KLP) was added for 30 min at room tempera-
ture, and the reaction was then stopped with 2 M HCl. The incu-
bations were performed in humid chambers, with intervening
washes (3   200  l PBS containing 0.05% Tween).
IL-10. Human Th1/Th2 Cytokine Cytometric Bead Array
kit was used (550749; Becton Dickinson). The assay was per-
formed according to the manufacturer’s recommendation.
Statistics. Shapiro-Francia W test was used for normality dis-
tribution test. Unpaired and paired two-tailed Student’s t tests
were used for statistical analyses. (Statview software designed for
Macintosh computers.)
Results
This study was designed to reveal possible immunoregu-
latory differences between PBMCs obtained from children
showing outgrown compared with active cow’s milk al-
lergy. The former group had presumably been subjected to
oral tolerance induction against milk allergens. All of the
included children had been on a cow’s milk-free diet for at
least 2 mo before the experimental milk challenge was per-
formed to distinguish clinically between the two groups.
Various immunological variables were examined both be-
fore and after this in vivo exposure to cow’s milk via the
gut for up to 1 wk. To evaluate milk-induced immune
stimulation and regulation, restimulation in vitro was per-
formed with the major milk allergen bovine  -LG. In ad-
dition, we performed polyclonal stimulation of PBMCs
with PHA to obtain a robust base-line response as a refer-
ence for functional Treg cell induction (see Discussion).
Peripheral blood from the two groups of children was
analyzed with regard to the frequency of CD4  T cells ex-
pressing CD25 and the modulation of this subset caused
by the in vivo milk challenge. The percentage of CD4 
CD25  T cells was fairly similar in the allergic and tolerant
groups before this challenge. After the in vivo milk ex-
posure, however, the tolerant group tended to show an
increased frequency of circulating CD25  cells (P  
0.07), whereas the number was significantly reduced (P  
0.01) in the allergic children (Fig. 1 A). Within this human
Figure 2. Expression of the maturation marker CD45RO (%) on cir-
culating CD4 CD25  T cells before and 1 wk after in vivo challenge
with cow’s milk. PBMCs were immunostained with mAbs, and
CD3 CD4 CD25  cells were gated to determine the frequency of
CD45RO  cells within this T cell subset.  , children with active allergy;
 , tolerant children (outgrown allergy). Student’s t test was used for sta-
tistical analysis.
Figure 3. Proliferation of PBMCs. (A) PBMCs were purified from
samples obtained before and 1 wk after in vivo challenge with cow’s milk
and then stimulated in vitro with bovine  -LG. Radioactive thymidine
(3H-Tdr) was added 6 d after addition of  -LG to the PBMC cultures.
The cells were harvested 12–16 h later. Incorporation of 3H-Tdr was
determined in a  -counter.  , children with active allergy;  , tolerant
children (outgrown allergy). (B) Similar samples and procedure as in A,
but stimulation was performed with PHA. Student’s t test was used for
statistical analysis.Karlsson et al. 1683
T cell subset, the fraction with a high level of CD25 has
been reported to be responsible for a down-regulatory
function (39), but we did not detect differences in the im-
munostaining intensity between the two groups of chil-
dren at either time points. Nevertheless, the CD4 CD25 
T cell subset profile was more distinct in the FACS® histo-
gram 1 wk after the in vivo milk challenge for children
with outgrown allergy than for those remaining allergic
(Fig. 1 A). Also, comparison between the tolerant and al-
lergic group with regard to the fraction of CD4 CD25  T
cells before and after the in vivo milk challenge revealed a
significant difference (P   0.03) in the modulation of this
subset relative to the prechallenge levels; although only
one out of seven of the allergic group showed an increased
frequency of the CD25  subset, this was the case for five
out of ten of the tolerant group (Fig. 1 B). Notably, the
percentage of CD3 CD4  cells showed a similar range for
both groups, both before (tolerant group: median 39.9%,
range 28.7–56.3%; allergic group: median 43.9, range
36.5–57.2%) and after (tolerant group: median 42.5%,
range 34.1–60.2%; allergic group: median 40.1%, range
24.9–56.3%) the challenge.
The increase of allergy in industrialized societies might
reflect an immature immune system due to reduced mi-
crobial exposure (4, 42). Therefore, we investigated the
maturation state of the CD4 CD25  T cells by examin-
ing their CD45RO expression. Approximately 30% of the
CD4 CD25  T cells in the tolerant children were posi-
tive for this marker in contrast to only 5% in the allergic
group; these values remained unchanged after the in vivo
milk challenge (Fig. 2). PBMCs were also immunostained
with mAbs to  4 7, CCR9, CCR4, CD8, surface
CTLA-4, CD40L, and CD45RA, but we did neither re-
veal any differences between the two groups of children
nor an effect of in vivo milk challenge on these markers
(unpublished data).
Interestingly, there was no significant difference between
the two groups of children in T cell proliferation induced
in vitro by  -LG when PBMCs collected before the in
vivo milk challenge were tested (Fig. 3 A). By contrast,
PBMCs obtained 1 wk after introduction of this challenge
showed significantly more proliferative activity against
 -LG for patients with active allergy compared with toler-
ant children (Fig. 3 A). Conversely, no difference in prolif-
eration at either time points was revealed by in vitro stimu-
lation of PBMCs with PHA (Fig. 3 B).
Although CD25 expression on CD4  T cells is associ-
ated with a regulatory function, it is not an exclusive
marker for Treg cells but can, instead, indicate a pro-
ductive effector function. To investigate whether the
CD4 CD25  subset in our PBMC cultures possessed reg-
ulatory capacity, we removed CD25  T cells from the
samples and performed in vitro stimulation with either
 -LG or the mitogen PHA (Fig. 4). Depleted PBMCs pu-
rified from blood obtained before in vivo milk challenge
tended to show increased proliferation in the allergic
group, perhaps reflecting a higher proliferative activity in
these children (Fig. 4 A), but no statistically significant dif-
ference was obtained. 1 wk after the milk challenge, de-
pleted PBMC cultures showed, on average, an almost five-
fold increase in the proliferative activity against  -LG in
the tolerant group compared with only twofold in the al-
lergic group (P   0.001), and there was moreover a signif-
icant increase (P   0.01) compared with the proliferative
level after depletion before the in vivo challenge. (Note
that the actual proliferation of undepleted PBMCs stimu-
lated with  -LG is shown in Fig. 3 A.) These results most
likely reflected that, after a long period of milk-restricted
diet, most  -LG specific memory T cells were probable
residing in the gut, whereas few were circulating. How-
ever, after the oral milk challenge specific T cells would
become activated and expanded in GALT and subse-
quently appear in the circulation before homing back to
the gut. Also, PHA tended to elicit augmented prolif-
eration after depletion of CD25  cells from PBMCs col-
lected from the tolerant children 1 wk after the challenge,
whereas no such enhancement was seen in unstimulated
cultures (Fig. 4).
Figure 4. Fold increase or de-
crease in proliferation after de-
pletion of CD25  cells from
PBMCs purified from blood be-
fore and 1 wk after in vivo chal-
lenge with cow’s milk. Predeple-
tion level (see Fig. 3 A) is set to
1 (dotted line). The depleted
and nondepleted PBMC sam-
ples  were tested for proliferative
activity, unstimulated and after in
vitro stimulation with bovine
 -LG or the mitogen PHA. Ra-
dioactive thymidine (3H-Tdr)
was added 6 d after addition of
antigens to the cell cultures. The
cells were harvested 12–16 h
later. Incorporation of 3H-Tdr
was determined in a  -counter.
Student’s t test was used for statistical analysis. For comparison with absolute proliferative activity (cpm values) of in vitro–stimulated PBMCs collected
from allergic and tolerant children before and after in vivo challenge, see Fig 3 A.CD25  Treg Cells in Food Allergy 1684
To examine whether the suppressive effect of CD25 
cells was mediated via a cell contact-dependent mechanism
or by soluble factors, we examined FACS®-sorted T cell
subsets in a transwell system. Due to severe ethical restraints
on blood sampling in children under 2 yr of age, we were
unable to purify autologous APCs for antigen-specific stim-
ulation in these experiments. Instead, we employed anti-
CD3/CD28 activation of the purified T cell subsets. When
CD25  and CD25  T cells isolated from PBMCs collected
1 wk after in vivo milk challenge were cocultured, a signif-
icantly reduced proliferative activity (P   0.03) was ob-
served compared with the result obtained when the two
subsets were separated by the transwell membrane (Fig. 5).
This suggested that at least part of the suppression was me-
diated via cell contact. When CD4 CD25  T cells were
cultured in both the upper and the lower chamber, the
proliferation was similar to that seen when the CD25  sub-
set was cultured in the lower chamber and the CD25  sub-
set in the upper chamber (Fig. 5).
In addition to the cell contact-mediated effect of Treg
cells, we examined production of the immunosuppressive
cytokines TGF-  (Fig. 6 A) and IL-10 (Fig. 6 B) in  -LG–
or PHA-stimulated PBMC cultures. We could not detect
any striking differences in cytokine concentrations for sam-
ples obtained either before or after the in vivo milk chal-
lenge. However, it was notable that PBMCs from the tol-
erant group tended to show increased TGF-  production
after  -LG stimulation when we compared the levels after
and before the in vivo milk challenge (P   0.27), and a
similarly increased trend associated with tolerance was ob-
served for IL-10 before the challenge when the two groups
were compared (P   0.14). Interestingly, the TGF-  re-
sponse was significantly decreased after challenge in the al-
lergic group (P   0.03), although it tended to be higher
Figure 5. Immunosuppression exerted by CD4 CD25  T cells in
peripheral blood from children tolerant against cow’s milk is partly cell
contact dependent. CD4 CD25  T cells and CD4 CD25  T cells were
FACS® sorted and cultured in transwell plates. In some wells, the
CD4 CD25  T cells were cultured in the upper chamber and the
CD4 CD25  T cells in the lower chamber, whereas in other plates both
subsets were cultured in the lower chambers. Additional controls con-
sisted of CD4 CD25  T cells cultured both in the upper and the lower
wells as indicated at the bottom of the figure. Stimulation was performed
with anti-CD3/CD28 beads for 48 h. The proliferative activity of
CD4 CD25  was tested by addition of radioactive thymidine (3H-Tdr),
and the cells were harvested 12 h later. Incorporation of 3H-Tdr was
determined in a  -counter. Note that individual subjects are indicated by
separate symbols, and that the y axis is broken. Student’s t test was used
for statistical analysis.
Figure 6. Generation of the immunosuppressive cytokines TGF- 1-
LAP and IL-10 by PBMCs purified from blood of allergic or tolerant
children before and 1 wk after in vivo challenge with cow’s milk. (A) Pro-
duction of TGF- 1-LAP determined in supernatants from PBMCs stim-
ulated for 96 h with  -LG (1 mg/ml) or PHA (50  g/ml) by subtracting
the TGF- 1-LAP concentration in unstimulated wells. (B) Production of
IL-10 under the same culture conditions as in A. Student’s t test was used
for statistical analysis.Karlsson et al. 1685
than in the tolerant group before challenge (P   0.08).
Such trends for cytokine changes were not apparent when
PHA was used to stimulate PBMCs (Fig. 6).
Discussion
This study showed that an in vivo milk challenge in-
duced Treg cells preferentially in previously cow’s milk–
allergic children who had become tolerant, that is, those
who clinically had outgrown their allergy. It is intriguing
how the intestinal immune system can discern between
pathogens and innocuous antigens such as dietary proteins
and respond by eliciting productive immunity or oral toler-
ance, respectively. The understanding of the latter phe-
nomenon has been hampered by intricate mechanistic
complexity involving T cell anergy, clonal deletion, skew-
ing of the cytokine profile (immune deviation), and the ac-
tion of different Treg cells. We established here for the first
time that human CD4 CD25  Treg cells induced via the
gut are involved in the control of food allergy, and that this
T cell subset after activation exerts its suppressive function
at least partially in a cell contact-dependent manner.
Our study compared phenotypic and functional charac-
teristics of PBMCs from children with clinically active or
outgrown cow’s milk allergy collected before and 1wk after
an in vivo challenge with cow’s milk. PBMCs from the
tolerant group showed reduced proliferation induced in
vitro by the major milk allergen  -LG. Furthermore, the
same children had a CD25  T cell subset within their
PBMCs that was able to suppress such proliferation. In this
group, 30% of CD4 CD25  T cells expressed the matura-
tion marker CD45RO both before and after challenge
with cow’s milk, whereas the corresponding figure was
only some 5% in the group with active allergy. All children
included in our study had negative skin prick test against
cow’s milk proteins and no elevated specific IgE antibody
levels in serum. This suggested that the observed symptoms
were most probably produced via cell-mediated immunity.
Approximately 50% of children suffering from food allergy
appear by standard diagnostic tests to have a non-IgE–
mediated allergic reaction (43, 44), presumably delayed-
type hypersensitivity, although the pathological process in
the gut may be indistinguishable from an atopic disorder
(45). We selected our patients to be homogeneously non-
atopic, but it would certainly be of interest in the future to
also study children with elevated IgE antibody levels against
food allergens in a similar experimental set-up.
Such studies in young children (with repeated sampling)
have profound ethical restrictions. Therefore, we had to de-
sign our in vitro experiments on the basis of the limited
blood volumes available. We also had to take into account
that with the large age range of the patients (6–56 mo), they
had a highly variable immunological history in terms of ex-
posure to antigens from vaccines and the environment. This
related not only to their systemic but also to their mucosal
immune system. Importantly, we investigated tolerance in-
duction via the gut, and recent animal experiments have
demonstrated that the systemic and local immunization
routes provide different results when it comes to dampening
of mucosal allergy (46). In view of this complex scenario,
we decided that PHA stimulation, rather than an arbitrarily
selected T cell–dependent antigen, would best ensure a
consistent base-line response as a reference for the mucosal
induction of Treg cells by cow’s milk proteins.
The in vitro proliferative activity of PBMCs against
 -LG was presumably a T cell recall response. Notably,
however, there was no significant difference when we
compared PBMCs collected from the two groups of chil-
dren before the in vivo cow’s milk challenge with regard to
proliferation elicited by  -LG, frequency of CD4 CD25 
T cells, and a suppressive effect of CD25  cells revealed by
their depletion. This result probably reflected that the pa-
tients with active allergy at this time point did not have a
substantially larger number of circulating memory T cells
specific for  -LG than tolerant children. The avoidance of
cow’s milk proteins for at least 2 mo before the challenge
might have reduced this number, and specific T cells acti-
vated in GALT and mesenteric LNs would presumably
start homing back to the intestinal lamina propria during
milk challenge. Thus, there was a reduced relative fre-
quency of circulating CD4 CD25  T cells in most allergic
children after the challenge (Fig. 1 B).
It is of note that the  -LG preparations contained LPS
comparable to an endotoxin activity of 5000 EU/ml at 5
mg/ml (Limulus Amebocyte Lysate test); but the poly-
clonal immunostimulation exerted by this contamination
did not mask the antigen-specific T cell response elicited
by  -LG in vitro (unpublished data). Interestingly, the pro-
liferative response of PBMCs against  -LG was signifi-
cantly decreased in milk-tolerant compared with allergic
children after the in vivo milk challenge. Our findings
therefore suggested that in the tolerant children this chal-
lenge had resulted in GALT activation and expansion not
only of specific effector T cells but also of CD4 CD25 
Treg cells, which suppressed the in vitro proliferative re-
sponse elicited by  -LG. The observed relative increase of
this circulating subset in half of the tolerant children 1 wk
after challenge (Fig. 1 B) was probably an underestimate
due to homing of allergen-activated T cells to the milk
protein–exposed gut lamina propria as alluded to above.
Although it was originally believed that CD4 CD25 
Treg cells are anergic, at least two independent reports re-
cently showed that mouse CD4 CD25  T cells initially
multiply in vivo after appropriate antigen stimulation (26,
47). We cannot exclude that the increased frequency of cir-
culating CD4 CD25  T cells after challenge in tolerant chil-
dren partly reflected expansion of ordinary memory–effector
T cells, but the striking increase (fivefold) of proliferative ac-
tivity against  -LG exhibited by PBMCs from these children
after depletion of CD25  cells strongly suggested that their
CD4 CD25  subset contained a substantial fraction of Treg
cells. This homeostatic mechanism most likely explained that
they had outgrown their cow’s milk allergy. For ethical rea-
sons we could not obtain blood at a later time point after theCD25  Treg Cells in Food Allergy 1686
milk challenge, so we have no information with regard to the
persistence of the elevated level of CD4 CD25  T cells in
the circulation of the tolerant children.
Expression of integrin  4 7 and CCR9 on T cells de-
termines their homing into the small intestinal lamina pro-
pria (48). We analyzed the frequency of T cells with these
markers, but there were no apparent differences between
the two groups of children. It has been reported that the
 4 7 subset is increased in peripheral blood from children
with cow’s milk allergy, but that finding was obtained with
T cells kept in culture for 1 wk (49). Also, it might be un-
realistic to expect that we should be able to identify a phe-
notypic change induced by milk proteins in the total circu-
lating pool of T cells with gut-homing properties.
Most functional studies of Treg cells have been per-
formed in animal models for autoimmunity, inflammatory
bowel disease, and transplantation. The first human studies
of CD4 CD25  Treg cells were in fact published quite re-
cently (39, 50–52). Evidence suggests that Treg cells may
be antigen nonspecific, at least in the effector phase, and
bystander suppression is a well-known phenomenon in oral
tolerance (53, 54). A nonspecific effect of Treg cells could
explain why we obtained a moderate enhancement of pro-
liferation against PHA in PBMCs from tolerant children af-
ter depletion of CD25  cells (Fig. 4). Altogether, our re-
sults implied that mucosally induced Treg cells responding
to milk antigens were involved in the observed tolerance
induction or, alternatively, that centrally generated Treg
cells had become activated and expanded in the children
with outgrown cow’s milk allergy.
Expression of CTLA-4 has been associated with human
CD4 CD25  Treg cells (55). This molecule is constitutively
expressed in the cytoplasm (27, 39), but once the cell is acti-
vated via the TcR complex it appears on the surface. How-
ever, the mechanistic role of surface CTLA-4 in cell con-
tact–dependent suppression in humans is debated. Several
studies show that blocking CTLA-4 with antibodies does
not abolish the suppressive activity of Treg cells (39, 51, 52).
We did not find any difference in the expression level of this
surface marker, either between the two groups of children or
the two time points for sampling of PBMCs. Nevertheless,
transwell experiments demonstrated that CD4 CD25  Treg
cells from milk-tolerant children exert their antiproliferative
effect via a contact-dependent mechanism. Regrettably, we
had no possibility to study the involvement of other inhibi-
tory molecules such as PD-1 (39, 56).
The role in oral tolerance of the immunosuppressive
cytokine TGF-  derived from so-called regulatory Th3
cells induced in experimental animals is extensively docu-
mented (57). The reduced production of TGF-  by
 -LG–stimulated PBMCs after the in vivo milk challenge
in the allergic group (Fig. 6 A) is in line with a recent study
by Perez-Machado et al. (58) which shows that T cells ob-
tained from duodenal mucosa of food-allergic children had
a decreased potential for TGF-  production compared
with healthy controls. Conversely, we found that PBMCs
stimulated by  -LG 1 wk after the in vivo challenge
tended to show increased production of TGF-  in chil-
dren with outgrown allergy, which could have contributed
to the observed suppressive effect on proliferation. The
major source for IL-10 production in  -LG–stimulated
PBMC cultures in our experiments remains unknown, and
the results obtained were inconclusive.
It has been shown in mouse models that the thymic epi-
thelium is important in the generation of naturally occur-
ring CD4 CD25  Treg cells involved in the maintenance
of tolerance (59). Because our study strongly suggests that
CD4 CD25  Treg cells reactive to dietary antigens can be
induced via the gut, it will be of considerable interest to in-
vestigate whether exosomes released from the intestinal ep-
ithelium play a role in the development of such cells. We
have previously obtained results indicative of a tolerance-
inductive function of epithelial exosomes produced in the
gut of experimental animals and therefore called these
structures “tolerosomes” (60).
In conclusion, the observations presented here provide
new insight into the possible relationship between mucosal
induction of CD4 CD25  Treg cells and protection against
food allergy in humans. These results may aid the develop-
ment of better diagnostic tools for such disorders and per-
haps contribute to promote a future goal of generating Treg
cells in vitro for immunotherapy of allergic diseases.
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